Phone: +44 (0)20 7554 5852

Tissues


The evolution of Stratified Medicine to more efficiently determine personalised treatment of a genetically profiled patient, has witnessed the extensive use of primary human samples for research which has necessitated innovative approaches in the preservation of the basic pathophysiology of biopsied samples ex vivo to improve interrogation of the proteomic, genomic and metabolomic characteristics of normal and malignant tissue biospecimens.

Historically, the preservation of biopsied tissues has utilised solutions based upon formulations first published early in the last century and therefore limited by analytical technology available during this period. The design formulations of currently available preservation media have simply evolved by the ad hoc addition of various chemicals without consideration of the many, interactive aspects of the biochemical and biophysical requisites required to maintain the overall balance of the cell's environment within the tissue sample following removal from the human body. Such solutions can only retain tissue viability for 4 – 24 hours.

The quest to more intimately replicate the fluid conditions subtending cells in all human tissues and organs resulted in the design principles utilised in the patented formulation of AQIX® RS-I, namely, that it should simulate the basic composition of the fluid environment surrounding every cell in all tissues and organs – the interstitial fluid (ISF) layer.

To accentuate the beneficial attributes of a fluid composition that simulates the ISF, a further patented feature of AQIX® RS-I is the superior ability of this fluid to control the acid-base (pH) balance during periods of 'cold' (hypothermic) or 'body temperature' (normothermic) conditions during storage, transportation or even perfusion of the isolated biopsy samples to enable diagnostic and drug design investigations for up to 72 hours following removal from donor patients.

Retention of the genetic and histological profiles of excised tissue samples following storage and transportation is a major requirement for diagnostic interrogation as the design of a personalised medication or therapy relies absolutely on such profiles. AQIX® RS-I has been shown in audit trials to achieve this goal with such profiles remaining unchanged over 46 – 72 hours.

While other tissue preservation solutions are 'tissue-specific', AQIX® RS-I has accommodated all types of normal and malignant biopsied tissues under varying temperature conditions and gives the added time advantage of allowing the procurement of 'fresh' tissues for future processing using conventional freezing or formalin fixation – a versatility not found in other commercial or 'home-brewed' media.

Published data/reports can be found on www.aqix.com web site.